Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to outperform standard drugs for rare blood cancer

NCT ID NCT04840602

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 8 times

Summary

This phase II trial is testing whether a combination of venetoclax and rituximab works better than current standard treatments (ibrutinib plus rituximab or zanubrutinib alone) for people with previously untreated Waldenstrom's macroglobulinemia, a rare type of blood cancer. The study will enroll 92 participants and measure how well the cancer responds to treatment. The goal is to find a more effective first-line therapy that can improve outcomes for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Venetoclax, rituximab, ibrutinib, zanubrutinib
What this could lead to
If successful, this trial could identify a more effective first-line treatment for Waldenstrom's macroglobulinemia, potentially improving response rates and delaying disease progression.
What could go wrong
This is a phase II trial with only 92 participants, so results are preliminary. The experimental combination may not prove superior to existing treatments, and side effects from these drugs can include infections, bleeding, and heart issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have had a confirmed diagnosis of Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL). Participants must have measurable disease as determined by IgM protein quantification. * IgM Spike: ≥ 500 mg/dL (≥ 5 g/L) * Extramedullary disease: The manifestation of a lymphoid mass outside of the bone marrow, resulting in enlargement in extramedullary organs such as the lymph nodes or spleen. Note: all participants must have measurable IgM spike, but are not required to have extramedullary disease * Testing to establish baseline disease status must be performed within 28 days prior to registration * Participants must have at least one of the criteria to require therapy for WM including: * Anemia * Thrombocytopenia * Neuropathy related to WM * Symptomatic hyperviscosity or serum viscosity levels ≥ 4.0 centipoises * WM associated glomerulonephritis or renal disease, bulky disease, or constitutional symptoms * Constitutional symptoms can be described as: * Unintentional weight loss \>= 10% within the previous 6 months prior to screening * Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for 2 or more weeks prior to screening without evidence of infection * Night sweats for more than 1 month prior to screening without evidence of infection * Clinically relevant fatigue which is not relieved by rest due to WM * Participants who require ongoing use or received a moderate or strong CYP3A inducer, moderate or strong CYP3A inhibitor, P-gp inhibitor within 7 days prior to the first dose of study drug will be excluded from the study. If such participants can be safely switched to an alternative agent, then the participants will be eligible to enroll * Participants must not have had prior systemic therapy. Prior therapy with rituximab will be allowed as long as the last rituximab dose was at least 6 months prior to registration * Participants must be \>= 18 years of age * Participants must have history and physical exam within 28 days prior to registration * Participants must have Zubrod performance status =\< 2 * Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) \>= 30 mL/min. Values must be obtained within 14 days prior to registration * Total bilirubin =\< 1.5 x IULN (institutional upper limit of the norm) (within 14 days prior to registration) * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =\< 3 x IULN (within 14 days prior to registration) * Alkaline phosphatase =\< 3 x IULN (within 14 days prior to registration) * Platelet count \>= 50,000 cells/mm\^3 (within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration * Hemoglobin \>= 7.0 g/dL (within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration * Absolute neutrophil count (ANC) \>= 1,000 cells/mm\^3 (within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration * Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration * Participants must be able to take and swallow oral medication (capsules) whole. Participants may not have any known impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) * Participants must not be intolerant to rituximab * Participants must not have known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding localized skin and nail bed fungal infections) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) 4 weeks prior to registration * Participants must not be seropositive for hepatitis C (except in the setting of sustained virologic response, defined as undetectable viral load at least 12 weeks after completion of antiviral therapy). Hepatitis C virus (HCV) testing is only required if clinically indicated or if the participant has a history of HCV * Participants must not consume grapefruit, Seville oranges or starfruit within 3 days prior to the first dose of venetoclax * Participants must not be pregnant or nursing because venetoclax has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" e.g., implants, injectables, combined oral contraceptives, some intrauterine devices \[IUDs\], complete abstinence, or sterilized partner) and a barrier method (e.g., condom, cervical ring, sponge, etc.). This also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures throughout the study and for at least 30 days after competition of therapy * No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years or watchful waiting is appropriate in the opinion of the treating physician. Also, malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 5 years, is permissible consideration of eligibility for this trial * Participants must be offered the opportunity to participate in specimen banking * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations * As a part of the Oncology Participant Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * CROSSOVER CRITERIA: Participants must have been registered and received treatment in the IR/Z or VR arm and must show progression of disease at any time during cycles 3-24 * CROSSOVER CRITERIA: In case of transformation to intermediate or high-grade lymphoma or development of Bing-Neel syndrome the participants will not undergo registration step 2 crossover and will be taken off the study * CROSSOVER CRITERIA: Participants must have Zubrod performance status =\< 2 * CROSSOVER CRITERIA: Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) \>= 30 mL/min. Values must be obtained within 14 days prior to registration * CROSSOVER CRITERIA: Participants must have no evidence of marked hepatic dysfunction on any recent liver function tests within 14 days prior to registration * CROSSOVER CRITERIA: Platelet count \>= 50,000 cells/mm\^3 (without within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration * CROSSOVER CRITERIA: Hemoglobin \>= 7.0 g/dL (without within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration * CROSSOVER CRITERIA: Absolute neutrophil count (ANC) \>= 1,000 cells/mm\^3 (without within 14 days prior to registration) * NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoplasmacytic lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoplasmacytic lymphoma Waldenstrom macroglobulinemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    127 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Adena Regional Medical Center

    SUSPENDED

    Chillicothe, Ohio, 45601, United States

  • Atrium Health Union/LCI-Union

    RECRUITING

    Monroe, North Carolina, 28112, United States

  • Banner University Medical Center - Tucson

    RECRUITING

    Tucson, Arizona, 85719, United States

  • Cancer Care Center of O'Fallon

    RECRUITING

    O'Fallon, Illinois, 62269, United States

  • Cancer Care Specialists of Illinois - Decatur

    RECRUITING

    Decatur, Illinois, 62526, United States

  • Cancer Hematology Centers - Flint

    RECRUITING

    Flint, Michigan, 48503, United States

  • Carle Cancer Center

    RECRUITING

    Urbana, Illinois, 61801, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Effingham

    RECRUITING

    Effingham, Illinois, 62401, United States

    Contact Email: •••••@•••••

  • Carle Physician Group-Mattoon/Charleston

    RECRUITING

    Mattoon, Illinois, 61938, United States

    Contact Email: •••••@•••••

  • Carle at The Riverfront

    RECRUITING

    Danville, Illinois, 61832, United States

    Contact Email: •••••@•••••

  • Carolinas Medical Center/Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28203, United States

  • Central Ohio Breast and Endocrine Surgery

    SUSPENDED

    Gahanna, Ohio, 43230, United States

  • Centralia Oncology Clinic

    RECRUITING

    Centralia, Illinois, 62801, United States

  • Chelsea Hospital

    RECRUITING

    Chelsea, Michigan, 48118, United States

  • City of Hope at Irvine Lennar

    RECRUITING

    Irvine, California, 92618, United States

  • Columbus Oncology and Hematology Associates Inc

    SUSPENDED

    Columbus, Ohio, 43214, United States

  • Crossroads Cancer Center

    RECRUITING

    Effingham, Illinois, 62401, United States

  • Delaware Health Center-Grady Cancer Center

    SUSPENDED

    Delaware, Ohio, 43015, United States

  • Doctors Hospital

    SUSPENDED

    Columbus, Ohio, 43228, United States

  • Dublin Methodist Hospital

    SUSPENDED

    Dublin, Ohio, 43016, United States

  • Fairfield Medical Center

    SUSPENDED

    Lancaster, Ohio, 43130, United States

  • Genesee Hematology Oncology PC

    SUSPENDED

    Flint, Michigan, 48503, United States

  • Genesis Healthcare System Cancer Care Center

    SUSPENDED

    Zanesville, Ohio, 43701, United States

  • Genesys Hurley Cancer Institute

    RECRUITING

    Flint, Michigan, 48503, United States

  • Glens Falls Hospital

    ACTIVE_NOT_RECRUITING

    Glens Falls, New York, 12801, United States

  • Grady Memorial Hospital

    SUSPENDED

    Delaware, Ohio, 43015, United States

  • Grant Medical Center

    SUSPENDED

    Columbus, Ohio, 43215, United States

  • Gundersen Lutheran Medical Center

    RECRUITING

    La Crosse, Wisconsin, 54601, United States

    Contact Email: •••••@•••••

  • Heartland Regional Medical Center

    RECRUITING

    Saint Joseph, Missouri, 64506, United States

  • Hematology Oncology Consultants-Clarkston

    RECRUITING

    Clarkston, Michigan, 48346, United States

  • Hennepin County Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55415, United States

  • Henry Ford Hospital

    RECRUITING

    Detroit, Michigan, 48202, United States

    Contact Email: •••••@•••••

  • Henry Ford Macomb Hospital-Clinton Township

    RECRUITING

    Clinton Township, Michigan, 48038, United States

    Contact Email: •••••@•••••

  • Henry Ford Medical Center-Columbus

    RECRUITING

    Novi, Michigan, 48377, United States

    Contact Email: •••••@•••••

  • Henry Ford West Bloomfield Hospital

    RECRUITING

    West Bloomfield, Michigan, 48322, United States

    Contact Email: •••••@•••••

  • Hurley Medical Center

    RECRUITING

    Flint, Michigan, 48503, United States

  • Huron Gastroenterology PC

    RECRUITING

    Ypsilanti, Michigan, 48106, United States

  • Knox Community Hospital

    SUSPENDED

    Mount Vernon, Ohio, 43050, United States

  • Levine Cancer Institute-Gaston

    RECRUITING

    Gastonia, North Carolina, 28054, United States

  • Licking Memorial Hospital

    RECRUITING

    Newark, Ohio, 43055, United States

  • Loyola University Medical Center

    RECRUITING

    Maywood, Illinois, 60153, United States

  • Marietta Memorial Hospital

    SUSPENDED

    Marietta, Ohio, 45750, United States

  • Marshfield Medical Center - Minocqua

    ACTIVE_NOT_RECRUITING

    Minocqua, Wisconsin, 54548, United States

  • Marshfield Medical Center - Weston

    RECRUITING

    Weston, Wisconsin, 54476, United States

    Contact Email: •••••@•••••

  • Marshfield Medical Center-EC Cancer Center

    ACTIVE_NOT_RECRUITING

    Eau Claire, Wisconsin, 54701, United States

  • Marshfield Medical Center-Marshfield

    ACTIVE_NOT_RECRUITING

    Marshfield, Wisconsin, 54449, United States

  • Marshfield Medical Center-Rice Lake

    ACTIVE_NOT_RECRUITING

    Rice Lake, Wisconsin, 54868, United States

  • Marshfield Medical Center-River Region at Stevens Point

    RECRUITING

    Stevens Point, Wisconsin, 54482, United States

    Contact Email: •••••@•••••

  • Mary Greeley Medical Center

    RECRUITING

    Ames, Iowa, 50010, United States

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • McFarland Clinic - Ames

    RECRUITING

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    SUSPENDED

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    SUSPENDED

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    RECRUITING

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    RECRUITING

    Fort Dodge, Iowa, 50501, United States

  • Memorial Sloan Kettering Basking Ridge

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    RECRUITING

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    RECRUITING

    Harrison, New York, 10604, United States

  • Mercy Health - Perrysburg Hospital

    SUSPENDED

    Perrysburg, Ohio, 43551, United States

  • Mercy Health - Saint Anne Hospital

    SUSPENDED

    Toledo, Ohio, 43623, United States

  • Mercy Health - Saint Vincent Hospital

    SUSPENDED

    Toledo, Ohio, 43608, United States

  • Mercy Hospital

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Mercy Hospital South

    RECRUITING

    St Louis, Missouri, 63128, United States

  • Michigan Healthcare Professionals Pontiac

    RECRUITING

    Pontiac, Michigan, 48341, United States

  • Mount Carmel East Hospital

    SUSPENDED

    Columbus, Ohio, 43213, United States

  • Mount Carmel Grove City Hospital

    SUSPENDED

    Grove City, Ohio, 43123, United States

  • Mount Carmel Health Center West

    SUSPENDED

    Columbus, Ohio, 43222, United States

  • MyMichigan Medical Center Saginaw

    RECRUITING

    Saginaw, Michigan, 48601, United States

  • MyMichigan Medical Center Tawas

    RECRUITING

    Tawas City, Michigan, 48764, United States

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    New York, New York, 10032, United States

  • Newark Radiation Oncology

    SUSPENDED

    Newark, Ohio, 43055, United States

  • Newland Medical Associates-Clarkston

    SUSPENDED

    Clarkston, Michigan, 48346, United States

  • Newland Medical Associates-Pontiac

    RECRUITING

    Pontiac, Michigan, 48341, United States

  • OhioHealth Mansfield Hospital

    SUSPENDED

    Mansfield, Ohio, 44903, United States

  • OhioHealth Marion General Hospital

    SUSPENDED

    Marion, Ohio, 43302, United States

  • Oncology Hematology Associates of Saginaw Valley PC

    SUSPENDED

    Saginaw, Michigan, 48604, United States

  • Park Nicollet Clinic - Saint Louis Park

    RECRUITING

    Saint Louis Park, Minnesota, 55416, United States

  • Providence Cancer Institute Clackamas Clinic

    SUSPENDED

    Clackamas, Oregon, 97015, United States

  • Providence Newberg Medical Center

    RECRUITING

    Newberg, Oregon, 97132, United States

    Contact Email: •••••@•••••

  • Providence Portland Medical Center

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Email: •••••@•••••

  • Providence Saint Vincent Medical Center

    RECRUITING

    Portland, Oregon, 97225, United States

    Contact Email: •••••@•••••

  • Providence Willamette Falls Medical Center

    RECRUITING

    Oregon City, Oregon, 97045, United States

    Contact Email: •••••@•••••

  • Regions Hospital

    RECRUITING

    Saint Paul, Minnesota, 55101, United States

  • Riverside Methodist Hospital

    SUSPENDED

    Columbus, Ohio, 43214, United States

  • Saint Alphonsus Cancer Care Center-Nampa

    RECRUITING

    Nampa, Idaho, 83687, United States

    Contact Email: •••••@•••••

  • Saint Ann's Hospital

    SUSPENDED

    Westerville, Ohio, 43081, United States

  • Saint Francis Medical Center

    RECRUITING

    Cape Girardeau, Missouri, 63703, United States

  • Saint Rita's Medical Center

    SUSPENDED

    Lima, Ohio, 45801, United States

  • Saint Vincent Frontier Cancer Center

    RECRUITING

    Billings, Montana, 59102, United States

  • Siteman Cancer Center at Christian Hospital

    ACTIVE_NOT_RECRUITING

    St Louis, Missouri, 63136, United States

  • Siteman Cancer Center at Saint Peters Hospital

    ACTIVE_NOT_RECRUITING

    City of Saint Peters, Missouri, 63376, United States

  • Siteman Cancer Center at West County Hospital

    ACTIVE_NOT_RECRUITING

    Creve Coeur, Missouri, 63141, United States

  • Siteman Cancer Center-South County

    ACTIVE_NOT_RECRUITING

    St Louis, Missouri, 63129, United States

  • Southeastern Medical Oncology Center-Clinton

    RECRUITING

    Clinton, North Carolina, 28328, United States

  • Southeastern Medical Oncology Center-Goldsboro

    RECRUITING

    Goldsboro, North Carolina, 27534, United States

  • Southeastern Medical Oncology Center-Jacksonville

    RECRUITING

    Jacksonville, North Carolina, 28546, United States

  • Southern Illinois University School of Medicine

    RECRUITING

    Springfield, Illinois, 62702, United States

  • Southern Ohio Medical Center

    SUSPENDED

    Portsmouth, Ohio, 45662, United States

  • Springfield Clinic

    RECRUITING

    Springfield, Illinois, 62702, United States

  • Springfield Memorial Hospital

    RECRUITING

    Springfield, Illinois, 62781, United States

  • Strecker Cancer Center-Belpre

    SUSPENDED

    Belpre, Ohio, 45714, United States

  • Swedish Cancer Institute-Edmonds

    RECRUITING

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute-Issaquah

    RECRUITING

    Issaquah, Washington, 98029, United States

  • Swedish Medical Center-First Hill

    RECRUITING

    Seattle, Washington, 98122, United States

  • The Mark H Zangmeister Center

    SUSPENDED

    Columbus, Ohio, 43219, United States

  • ThedaCare Regional Cancer Center

    RECRUITING

    Appleton, Wisconsin, 54911, United States

    Contact Email: •••••@•••••

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    RECRUITING

    Brighton, Michigan, 48114, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    RECRUITING

    Canton, Michigan, 48188, United States

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    RECRUITING

    Chelsea, Michigan, 48118, United States

  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

    RECRUITING

    Ypsilanti, Michigan, 48197, United States

  • Trinity Health Medical Center - Brighton

    RECRUITING

    Brighton, Michigan, 48114, United States

  • Trinity Health Medical Center - Canton

    RECRUITING

    Canton, Michigan, 48188, United States

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor

    RECRUITING

    Ann Arbor, Michigan, 48106, United States

  • Trinity Health Saint Joseph Mercy Oakland Hospital

    RECRUITING

    Pontiac, Michigan, 48341, United States

  • Trinity Health Saint Mary Mercy Livonia Hospital

    RECRUITING

    Livonia, Michigan, 48154, United States

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    RECRUITING

    Coral Gables, Florida, 33146, United States

  • UM Sylvester Comprehensive Cancer Center at Coral Springs

    RECRUITING

    Coral Springs, Florida, 33065, United States

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    RECRUITING

    Deerfield Beach, Florida, 33442, United States

  • UM Sylvester Comprehensive Cancer Center at Doral

    RECRUITING

    Doral, Florida, 33166, United States

  • UM Sylvester Comprehensive Cancer Center at Hollywood

    RECRUITING

    Hollywood, Florida, 33021, United States

  • UM Sylvester Comprehensive Cancer Center at Kendall

    RECRUITING

    Miami, Florida, 33176, United States

  • UM Sylvester Comprehensive Cancer Center at Plantation

    RECRUITING

    Plantation, Florida, 33324, United States

  • United Hospital

    RECRUITING

    Saint Paul, Minnesota, 55102, United States

  • University of Arizona Cancer Center-North Campus

    RECRUITING

    Tucson, Arizona, 85719, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia

    RECRUITING

    North Miami, Florida, 33181, United States

  • University of Michigan Health - Sparrow Lansing

    RECRUITING

    Lansing, Michigan, 48912, United States

  • University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

  • VCU Massey Comprehensive Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Washington University School of Medicine

    ACTIVE_NOT_RECRUITING

    St Louis, Missouri, 63110, United States

  • Wayne State University/Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

    Contact Email: •••••@•••••

  • Weisberg Cancer Treatment Center

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.